ClinicalTrials.gg
RecruitingNCT05797519VISTAUpdated Aug 13, 2026

Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation

An interventional study of VDyne Transcatheter Tricuspid Valve Replacement System in Tricuspid Regurgitation, Tricuspid Valve Disease and Tricuspid Valvular Disorders, sponsored by VDyne, Inc.. Recruiting at 21 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by VDyne, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this clinical study is to collect safety and efficacy data of the VDyne System to support Conformitè Europëenne (CE) Mark of the VDyne System.

02

Conditions studied

  • Tricuspid Regurgitation
  • Tricuspid Valve Disease
  • Tricuspid Valvular Disorders
03

In context

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

This study's planned enrollment of 120 is above the median of 60 across 129 interventional studies indexed under Tricuspid Valve Insufficiency.

Browse Tricuspid Valve Insufficiency studies →

Lead sponsor

VDyne, Inc. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Severe or greater tricuspid valve regurgitation of primary or secondary etiology.
  2. class ≥ II. If NYHA Class IV, patient must be ambulatory.
  3. Subject is adequately treated with medical therapy for heart failure >30 days prior to index procedure, including a diuretic.
  4. Heart Team determines patient is a recommended candidate for the VDyne System.
  5. Age 18 years or older at time of the index procedure.
  6. Clinical Screening Committee (CSC) and Imaging Core Labs confirm suitability for treatment with the VDyne System.

Exclusion criteria

Exclusion Criteria:

VDYNE SYSTEM SUITABILITY

  1. Patient anatomy (cardiac and vascular) is not suitable for the VDyne System as assessed by Imaging Core Labs, Sponsor and/or Clinical Screening Committee (CSC)
  2. Intolerance to procedural anticoagulation or post-procedural antiplatelet/anticoagulation regimen that cannot be medically managed
  3. to nickel or titanium

    CLINICAL EXCLUSION CRITERIA (assessed by pre-procedural imaging)

  4. (LVEF) \<30%
  5. Severe RV dysfunction as assessed by the Clinical Screening Committee (CSC).
  6. Significant abnormalities of the tricuspid valve and sub-valvular apparatus
  7. Sepsis including active infective endocarditis (IE) (within the last 6 months)
  8. Right ventricular, atrial thrombus, vegetation or mass on tricuspid valve.
  9. Severe tricuspid annular or leaflets calcification
  10. Systolic pulmonary hypertension with systolic pulmonary artery pressure >70 mmHg or pulmonary vascular resistance (PVR) >5 wood units as determined by RHC.
  11. History of rheumatic fever that impacts the native tricuspid valve or surrounding structures.

    CONCOMITANT PROCEDURES

  12. Significant coronary artery disease requiring treatment such as symptomatic, unresolved multi-vessel or unprotected left main coronary artery disease (CAD).
  13. Any planned surgery or interventional procedure within 30 days prior to or following the implant procedure. This includes any planned concomitant cardiovascular procedure [e.g. Coronary Artery Bypass Grafting (CABG), percutaneous coronary intervention (PCI), pulmonary vein ablation, left atrial appendage occlusion, septal defect repair, etc.]
  14. Unresolved severe symptomatic carotid stenosis (> 70% by ultrasound)
  15. Cardiac resynchronization therapy device or implantable pulse generator implanted within 60 days of planned implant procedure.
  16. Permanent pacing leads that will interfere with delivery or implantation of the VDyne Valve.
  17. Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices at the time of planned implant procedure.
  18. Prior tricuspid valve surgery or catheter-based therapy with permanent residual device(s) implanted that would preclude delivery or implantation of the VDyne Valve (e.g. valve replacement, edge to edge repair, etc.)
  19. Significant valvular heart disease requiring intervention other than the tricuspid valve
  20. Known significant intracardiac shunt [e.g. septal defect), patent foramen ovales (PFOs) without significant shunts are allowed]

    COMORBIDITIES

  21. Cerebrovascular accident (stroke, ) within 6 months of treatment procedure
  22. Severe lung disease [severe (COPD) or continuous use of home oxygen or oral ]
  23. Acute myocardial infarction (AMI) within 30 days
  24. Significant renal dysfunction (\<30 ml/min/1.73m2) or on dialysis
  25. End-stage liver disease (MELD > 11 and class C)
  26. Bleeding requiring transfusion within 30 days
  27. Coagulopathy or other clotting disorder that cannot be medically managed
  28. Chronic or other condition that could impair healing response
  29. Any of the following: leukopenia, chronic anemia [ (Hgb) \< 9], current thrombocytopenia ( \<70), history of bleeding diathesis, or coagulopathy
  30. Unwilling to receive blood products GENERAL EXCLUSION CRITERIA
  31. Known hypersensitivity or to procedural or post-procedural medications (e.g., contrast solution) which cannot be adequately managed medically
  32. less than 12 months due to non-cardiac comorbidities
  33. Treatment is not expected to provide benefit (futile)
  34. Current IV Drug user (must be free drug abuse for > 1 year)
  35. Pregnant, lactating or planning pregnancy during the course of the study
  36. Vulnerable patient groups (minors, cognitively impaired persons, prisoners, persons whose willingness to volunteer could be unduly influenced by the expectation of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate, such as students, residents, and employees)
  37. Currently participating in an drug or device trial that has not reached its primary endpoint or is likely to interfere with this study
  38. Patient (or legal guardian) unable or unwilling to provide written before study-specific procedures are conducted
  39. Patient unable or unwilling to comply with study required testing and follow-up visits.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    VDyne System Treatment Arm

    Device: VDyne Transcatheter Tricuspid Valve Replacement System

Interventions

  • DeviceVDyne Transcatheter Tricuspid Valve Replacement System

    The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System.

    Also known as: VDyne System, VDyne Tricuspid System, VDyne Valve System, VDyne Valve

06

What researchers measure

Primary outcomes

  1. The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE)

    The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC).

    Time frame: 30 days post-procedure

  2. Change in tricuspid valve regurgitation as measured by the Imaging Core Labs

    Change in tricuspid valve regurgitation as measured by the Imaging Core Labs

    Time frame: From Baseline to 1 month post-procedure

  3. Changes in quality of life as measured by the KCCQ changes.

    Changes in quality of life as measured by the KCCQ changes. Higher score indicates worse outcome.

    Time frame: From Baseline to 1 month post-procedure

  4. Changes in functional capacity (6-minute walk test)

    Changes in functional capacity (6-minute walk test)

    Time frame: From Baseline to 1 month post-procedure

  5. Changes in symptom status (NYHA class)

    Changes in symptom status (NYHA class)

    Time frame: From Baseline to 1 month post-procedure

Secondary outcomes

  1. The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE)

    The percentage of subjects with Device- and/or Procedure related Major Adverse Events as classified by the CEC

    Time frame: From Baseline to 1 year post-procedure

  2. Change in tricuspid valve regurgitation as measured by the Imaging Core Lab

    Change in tricuspid valve regurgitation as measured by the Imaging Core Lab

    Time frame: From Baseline to 3 months, 6 months and 1 year

  3. Intra-Procedural success

    Rate of successful implantation of the VDyne Valve using the VDyne Delivery System, absence of procedural mortality or stroke, adequate performance of the VDyne Valve, no device-related obstruction of forward flow or pulmonary embolism and \& freedom from emergency surgery or reintervention during the first 24 hours related to the device or access procedure.

    Time frame: From implant start time to procedure room exit

  4. Clinical success

    Absence of procedural mortality, proper position of the device with adequate performance, freedom from unplanned surgical or interventional procedures related to the device or procedure, absence of major adverse events, device related pulmonary embolism and obstruction of forward flow, any severe hemodynamic compromise leading to heart transplantation or major cardiac assistance or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.

    Time frame: From implant to 30 days post implant

  5. Changes in symptom status (NYHA class)

    Changes in symptom status (NYHA class)

    Time frame: From Baseline to 3 months, 6 months and 1 year

  6. Changes in functional capacity (6 minute walk test)

    Changes in functional capacity (6 minute walk test)

    Time frame: From Baseline to 3 months, 6 months and 1 year

  7. Changes in quality of life as measured by the KCCQ changes.

    Changes in quality of life as measured by the KCCQ changes. Higher score indicates worse outcome.

    Time frame: From Baseline to 3 months, 6 months and 1 year

  8. Clinical success

    No rehospitalizations or reinterventions for the underlying condition (e.g., tricuspid regurgitation/stenosis, heart failure);

    Time frame: From implant to 1 Year post-implant

  9. Clinical success

    Improvement from baseline in symptoms (e.g., NYHA improvement by \>1 functional class); and/or Improvement from baseline in functional status (e.g., 6-min walk test improvement by \>30 m); and/or Improvement from baseline in quality-of-life (e.g., Kansas City Cardiomyopathy Questionnaire improvement by \>10)

    Time frame: From implant to 1 Year post-implant

07

Study locations

14 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There is not a plan to make IPD available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 45 months is above that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
Apr 4, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2030
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05797519
Lead sponsor
VDyne, Inc.
Responsible party
Sponsor
First posted
Apr 4, 2023
Start date
Mar 1, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Aug 13, 2026

Study contacts

Vinny Podichetty
Contact
vpodichetty@vdyne.com
+1.763.777.5969
Pree Bassi
Contact
pbassi@vdyne.com
+1-612-438-6888
Vinny Podichetty
study director · VDyne, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion